Jennifer J. Rhodes - Feb 6, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, CHIEF LEGAL OFFICER, SEC
Signature
/s/ Jennifer J. Rhodes
Stock symbol
ACAD
Transactions as of
Feb 6, 2024
Transactions value $
$0
Form type
4
Date filed
2/8/2024, 05:09 PM
Previous filing
Mar 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +127K $0.00 127K Feb 6, 2024 Common Stock 127K $25.74 Direct F1
transaction ACAD Restricted Stock Units Award $0 +25.9K $0.00 25.9K Feb 6, 2024 Common Stock 25.9K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on February 6, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 50% of the restricted stock units vest on February 6, 2026 and 25% vest on each of February 6, 2027 and February 6, 2028.